A2E-Saposin B Assay for Urinary Macular Degeneration Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays are inadequate for detecting the presence or severity of macular degeneration, particularly due to the lack of methods for identifying toxic compounds like A2E in the human eye, which are associated with the progression of the disease.
Innovation Solution
An assay using Saposin B to capture A2E from urine samples, followed by immunoprecipitation and mass spectroscopy for measurement, enabling the detection and quantification of A2E levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used for detecting macular degeneration, then existing diagnostic approaches can be maintained, but the ability to detect A2E and assess disease severity is insufficient
Solution Approach 1:
Saposin B is used as an intermediary substance to bind A2E in urine samples, enabling the detection of A2E through immunoprecipitation. The lipid-binding protein acts as a mediator that captures A2E, allowing for subsequent measurement via mass spectrometry that would otherwise be difficult to achieve directly
Solution Approach 2:
The assay performs preliminary capture of A2E using Saposin B binding before the actual measurement step. This preliminary action of binding and concentrating A2E in the urine sample enables more accurate detection and quantification in the subsequent mass spectrometry analysis
2Reliability
If no specific assay is available for detecting A2E, then general diagnostic methods can be used, but the presence and severity of macular degeneration cannot be accurately detected
Solution Approach 1:
The diagnostic approach is segmented into distinct components: Saposin B for A2E capture, immunoprecipitation substrates for separation, and mass spectrometry for measurement. This segmentation allows each component to perform its specific function optimally, achieving reliable diagnosis through a coordinated multi-step process
Solution Approach 2:
Saposin B serves multiple functions in the assay system: it acts as a binding agent for A2E, facilitates immunoprecipitation, and enables concentration of the target analyte. This multi-functionality reduces the need for multiple separate reagents and simplifies the overall assay design while maintaining high diagnostic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate diagnosis of macular degeneration by correlating A2E levels in urine with disease progression, facilitating timely intervention.
Implementation Method 1
The lipid binding protein Saposin B is used to capture A2E in a sample
Implementation Method 2
The captured A2E may then be extracted from the urine using immunoprecipitation
Data Source
AI summary
An assay and kit for detecting N-retinylidene-N-retinylethanolamine (A2E) in a sample that uses a lipid binding protein, such as Saposin B, to capture A2E in the sample and assist in the extraction and measurement of A2E via mass spectroscopy. A2E thus serves as a marker for macular degeneration so that the assay and kit of the invention can be used to detect the presence or severity of macular degeneration.